AbCellera Biologics Inc. filed a current report on August 10, 2026, announcing positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor antagonist antibody.

Key Highlights

  • Trial readout: AbCellera disclosed positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635.
  • Investigational asset: ABCL635 is described in the filing as an investigational neurokinin 3 receptor (NK3R) antagonist antibody.
  • Investor call: The company held an investor conference call and webcast at 4:30 a.m. Pacific Time (7:30 a.m. Eastern Time) on August 10, 2026.
  • Exhibits furnished: A press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2), both dated August 10, 2026, were furnished with the filing.
  • Signed by: The report was signed by Carl L. G. Hansen, Ph.D., Chief Executive Officer and Director, as Principal Executive Officer.

AbCellera's ABCL635 Clinical Milestone and Disclosure Details

According to the filing, AbCellera Biologics Inc. (NASDAQ: ABCL), a biopharmaceutical company incorporated in British Columbia and headquartered in Vancouver, BC, issued a press release on August 10, 2026, announcing positive top-line results from the Phase 2 portion of a Phase 1/2 clinical trial. The trial evaluates ABCL635, which the filing characterizes as an investigational NK3R antagonist antibody. The neurokinin 3 receptor is a target class relevant to conditions including vasomotor symptoms, and ABCL635 represents a biologics-based approach in this area, according to the company's own characterization in the disclosure.

The filing was made under Item 7.01 (Regulation FD) and notes that the information furnished, including the press release and investor presentation attached as exhibits, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The company also held a webcast and investor conference call on the same date as the announcement to accompany the top-line data release. Two exhibits were furnished: Exhibit 99.1, a press release, and Exhibit 99.2, an investor presentation, both dated August 10, 2026.

The report was signed by Carl L. G. Hansen, Ph.D., in his capacity as Chief Executive Officer, Director, and Principal Executive Officer of AbCellera Biologics Inc. The company's common shares are registered on The Nasdaq Stock Market LLC under the trading symbol ABCL, as stated in the filing's registered-securities table.

What Was Disclosed

AbCellera Biologics Inc. filed a current report on August 10, 2026, disclosing positive top-line results from the Phase 2 portion of a Phase 1/2 clinical trial of ABCL635, an investigational NK3R antagonist antibody, along with an accompanying press release and investor presentation as furnished exhibits.